QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

22,097 signal articles · 432 in last 24h · 106,605 total before filter · latest 1h ago
432last 24h
2467last 7d
477● bullish (7d)
245● bearish (7d)
200publishers
AllMacro193Earnings1523M&A123Regulatory15Product8Analyst24
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
Mastercard Q2 Earnings Call Highlights
MarketBeat7d agoneutral
Mastercard Q2 Earnings Call Highlights

Mastercard (NYSE:MA) reported second-quarter 2026 results that exceeded its expectations, supported by continued consumer and business spending, cross-border activity and demand for its value-added services. On a non-GAAP, currency-neutral basis, net revenue rose 12% year over year, adjusted net in

Private credit roundup: Earnings hold up as defaults, redemptions remain elevated
Reuters7d agoneutral
Private credit roundup: Earnings hold up as defaults, redemptions remain elevated

Ares Capital and Blue Owl Capital reported resilient second-quarter results this week, while Ares Management posted record fundraising, highlighting continued institutional demand for private credit despite rising defaults, ‌retail redemptions and liquidity concerns. Ares Management, one of the industry's largest players, raised a record $36 billion ‌in the second quarter, including $23.7 billion for its credit strategies. Assets under management rose 17% from a year earlier to $671.3 billion.

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.
Barrons.com7d agobullish
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.